2 result(s) displayed (1 - 2 of 2):

Genzyme's Termeer on the hidden costs of biotech deals (from Corporate Dealmaker)

The credit crunch is making this a good time for pharma and bigger biotech companies to acquire young biotech firms with promising research but insufficient resources to take it forward. But Henri Termeer (pictured), CEO of Genzyme Corp. and one of the most experienced acquirers of other biotechs (as we...

Posted on January 14, 2009 11:04 AM

Genzyme is hungry (from Corporate Dealmaker)

As the only big biotech dedicated to relentless acquisition, the company may point the way to consolidation in the sector.

Posted on October 15, 2007 7:53 PM